American Journal of Kidney Diseases
Volume 54, Issue 1 , Pages 77-85, July 2009

Immunogenicity of a Standard Trivalent Influenza Vaccine in Patients on Long-term Hemodialysis: An Open-Label Trial

  • Johan Scharpé, MD

      Affiliations

    • Division of Nephrology, Department of Medicine, University Hospital Gasthuisberg, Leuven, Belgium
  • ,
  • Willy E. Peetermans, MD, PhD

      Affiliations

    • Division of Infectious Diseases, Department of Medicine, University Hospital Gasthuisberg, Leuven, Belgium
  • ,
  • Johan Vanwalleghem, MD

      Affiliations

    • Division of Nephrology, Department of Medicine, Virga Jesse Hospital Hasselt, Belgium
  • ,
  • Bart Maes, MD, PhD

      Affiliations

    • Division of Nephrology, Department of Medicine, University Hospital Gasthuisberg, Leuven, Belgium
  • ,
  • Bert Bammens, MD, PhD

      Affiliations

    • Division of Nephrology, Department of Medicine, University Hospital Gasthuisberg, Leuven, Belgium
  • ,
  • Kathleen Claes, MD

      Affiliations

    • Division of Nephrology, Department of Medicine, University Hospital Gasthuisberg, Leuven, Belgium
  • ,
  • André D. Osterhaus, MD, PhD

      Affiliations

    • Department of Virology, Erasmus MC, Rotterdam, The Netherlands
  • ,
  • Yves Vanrenterghem, MD, PhD

      Affiliations

    • Division of Nephrology, Department of Medicine, University Hospital Gasthuisberg, Leuven, Belgium
  • ,
  • Pieter Evenepoel, MD, PhD

      Affiliations

    • Division of Nephrology, Department of Medicine, University Hospital Gasthuisberg, Leuven, Belgium
    • Corresponding Author InformationAddress correspondence to Pieter Evenepoel, MD, PhD, Dienst Nefrologie, Universitair Ziekenhuis Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium

Received 8 August 2008; accepted 20 November 2008. published online 02 April 2009.

Background

Disturbances in acquired immunity are considered to be responsible, at least in part, for the high infection rate and inadequate response to vaccinations observed in hemodialysis (HD) patients. The present prospective trial aimed to: (1) evaluate the immunogenicity of a standard influenza vaccine in HD patients, and (2) identify determinants of the immune response.

Study Design

Prospective interventional open-label study.

Setting & Participants

201 long-term HD patients and 41 healthy volunteers.

Intervention

Vaccination with a standard trivalent inactivated influenza vaccine.

Outcomes

The primary outcome was seroprotection rate, defined as percentage of participants with an antibody titer of 40 or greater 1 month after vaccination.

Measurements

All antibody titers were determined in duplicate by using the hemagglutination inhibition assay. Regression analyses were performed to investigate the association between demographics, uremic retention solutes (including p–cresol), inflammation, nutrition, iron status, trace elements, and immune response in HD patients.

Results

More than 80% of HD patients showed seroprotection after vaccination. The immune response of HD patients was similar to that of healthy volunteers. Booster vaccination did not improve the immune response. High serum ferritin level was the only parameter independently associated with a better vaccination-induced antibody response in HD patients.

Limitations

A high seroprotection rate at baseline undermined the power to identify clinical determinants of the immune response.

Conclusions

Influenza vaccination is as efficacious in HD patients as in healthy volunteers. With the exception of serum ferritin, none of the investigated parameters of nutrition, inflammation, and dialysis adequacy had a significant impact on the immune response. Our data support annual vaccination of HD patients and question the clinical relevance of disturbances in acquired immunity in contemporary HD patients.

Index Words: Hemodialysis, influenza, vaccination

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Originally published online as doi: 10.1053/j.ajkd.2008.11.032 on April 2, 2009.

 Trial registration: www.clinicaltrials.gov; study number: NCT00776750.

PII: S0272-6386(09)00049-3

doi:10.1053/j.ajkd.2008.11.032

Refers to article:

  • Overcoming Challenges to Influenza Vaccination in Patients With CKD

    Alexander J. Kallen, Anthony E. Fiore
    American Journal of Kidney Diseases July 2009 (Vol. 54, Issue 1, Pages 6-9)

American Journal of Kidney Diseases
Volume 54, Issue 1 , Pages 77-85, July 2009